{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:06:27Z","timestamp":1788444387360,"version":"build-2803163510"},"reference-count":94,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T00:00:00Z","timestamp":1507161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0185946","type":"journal-article","created":{"date-parts":[[2017,10,5]],"date-time":"2017-10-05T17:49:58Z","timestamp":1507225798000},"page":"e0185946","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":36,"title":["Novel multipurpose pod-intravaginal ring for the prevention of HIV, HSV, and unintended pregnancy: Pharmacokinetic evaluation in a macaque model"],"prefix":"10.1371","volume":"12","author":[{"given":"James M.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Moss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priya","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Butkyavichene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjula","family":"Gunawardana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Fanter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine S.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debbie","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanon","family":"Ellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jining","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Marzinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig W.","family":"Hendrix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1558-5649","authenticated-orcid":true,"given":"Marc M.","family":"Baum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,10,5]]},"reference":[{"key":"ref1","article-title":"Delivering an AIDS-free Generation","author":"DL Birx","year":"2014"},{"key":"ref2","article-title":"Fast-Track: Ending the AIDS Epidemic by 2030","year":"2014"},{"key":"ref3","article-title":"Prevention Gap Report","year":"2016"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1086\/338231","article-title":"Risk of Human Immunodeficiency Virus Infection in Herpes Simplex Virus Type 2 Seropositive Persons: a Meta-analysis","volume":"185","author":"A Wald","year":"2002","journal-title":"J Infect Dis"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1086\/345867","article-title":"Herpes Simplex Virus Type 2 Infection as a Risk Factor for Human Immunodeficiency Virus Acquisition in Men Who Have Sex with Men","volume":"187","author":"C Renzi","year":"2003","journal-title":"J Infect Dis"},{"issue":"10","key":"ref6","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1086\/368357","article-title":"Recent Herpes Simplex Virus Type 2 Infection and the Risk of Human Immunodeficiency Virus Type 1 Acquisition in India","volume":"187","author":"SJ Reynolds","year":"2003","journal-title":"J Infect Dis"},{"issue":"11","key":"ref7","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1097\/OLQ.0b013e31822e60b6","article-title":"Prevalence of Herpes Simplex Virus Type 2 Infection, Human Immunodeficiency Virus\/Herpes Simplex Virus Type 2 Coinfection, and Associated Risk Factors in a National, Population-based Survey in Kenya","volume":"38","author":"N Mugo","year":"2011","journal-title":"Sex Transm Dis"},{"issue":"5","key":"ref8","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/00126334-200404150-00001","article-title":"The Effects of Herpes Simplex Virus-2 on HIV-1 Acquisition and Transmission: A Review of Two Overlapping Epidemics","volume":"35","author":"L Corey","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/01.aids.0000198081.09337.a7","article-title":"Herpes Simplex Virus 2 Infection Increases HIV Acquisition in Men and Women: Systematic Review and Meta-analysis of Longitudinal Studies","volume":"20","author":"EE Freeman","year":"2006","journal-title":"Aids"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1086\/343739","article-title":"Age-specific Prevalence of Infection with Herpes Simplex Virus Types 2 and 1: A Global Review","volume":"186","author":"JS Smith","year":"2002","journal-title":"J Infect Dis"},{"issue":"4","key":"ref11","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1086\/315836","article-title":"Interactions Between Herpes Simplex Virus Type 2 and Human Immunodeficiency Virus Type 1 Infection in African Women: Opportunities for Intervention","volume":"182","author":"FX Mbopi-Keou","year":"2000","journal-title":"J Infect Dis"},{"issue":"5","key":"ref12","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/mi.2014.3","article-title":"Herpes Simplex Virus Type-2 Stimulates HIV-1 Replication in Cervical Tissues: Implications for HIV-1 Transmission and Efficacy of Anti-HIV-1 Microbicides","volume":"7","author":"C Rollenhagen","year":"2014","journal-title":"Mucosal Immunol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"I17","DOI":"10.1136\/sti.2006.023549","article-title":"Proportion of New HIV Infections Attributable to Herpes Simplex 2 Increases over Time: Simulations of the Changing Role of Sexually Transmitted Infections in sub-Saharan African HIV Epidemics","volume":"83","author":"EE Freeman","year":"2007","journal-title":"Sex Transm Infect"},{"issue":"27","key":"ref14","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men","volume":"363","author":"RM Grant","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"ref15","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women","volume":"367","author":"JM Baeten","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMoa1110711","article-title":"Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana","volume":"367","author":"MC Thigpen","year":"2012","journal-title":"N Engl J Med"},{"issue":"9883","key":"ref17","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","article-title":"Antiretroviral Prophylaxis for HIV Infection in Injecting Drug Users in Bangkok, Thailand (the Bangkok Tenofovir Study): a Randomised, Double-blind, Placebo-controlled Phase 3 Trial","volume":"381","author":"K Choopanya","year":"2013","journal-title":"Lancet"},{"issue":"23","key":"ref18","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","article-title":"On-demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection","volume":"373","author":"JM Molina","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"ref19","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/QAI.0000000000001129","article-title":"Preexposure Prophylaxis for HIV Prevention in a Large Integrated Health Care System: Adherence, Renal Safety, and Discontinuation","volume":"73","author":"JL Marcus","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"10013","key":"ref20","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(15)00056-2","article-title":"Pre-exposure Prophylaxis to Prevent the Acquisition of HIV-1 Infection (PROUD): Effectiveness Results from the Pilot Phase of a Pragmatic Open-label Randomised Trial","volume":"387","author":"S McCormack","year":"2016","journal-title":"Lancet"},{"issue":"7","key":"ref21","doi-asserted-by":"crossref","first-page":"F13","DOI":"10.1097\/QAD.0b013e3283522272","article-title":"Unraveling the Divergent Results of Pre-exposure Prophylaxis Trials for HIV Prevention","volume":"26","author":"A van der Straten","year":"2012","journal-title":"Aids"},{"issue":"6","key":"ref22","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/BF00314990","article-title":"Dosage Frequency and Drug Compliance Behavior\u2014a Comparative Study on Compliance with a Medication to Be Taken Twice or 4 Times Daily","volume":"41","author":"W Kruse","year":"1991","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"ref23","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/S0169-409X(02)00090-X","article-title":"Implantable, Polymeric Systems for Modulated Drug Delivery","volume":"54","author":"S Sershen","year":"2002","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"ref24","doi-asserted-by":"crossref","first-page":"295","DOI":"10.2174\/1568005033481079","article-title":"Is Resistance Futile?","volume":"3","author":"VD Kutilek","year":"2003","journal-title":"Curr Drug Targets Infect Disord"},{"issue":"9","key":"ref25","doi-asserted-by":"crossref","first-page":"728","DOI":"10.18553\/jmcp.2009.15.9.728","article-title":"Comparing Adherence and Persistence Across 6 Chronic Medication Classes","volume":"15","author":"J Yeaw","year":"2009","journal-title":"J Manag Care Pharm"},{"key":"ref26","first-page":"221","article-title":"Drug Delivery and Development of Anti-HIV Microbicides","author":"JA Moss","year":"2014"},{"issue":"10","key":"ref27","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.2217\/fvl.15.83","article-title":"Injectable and Implantable Antiretroviral Strategies for HIV Prevention","volume":"10","author":"I McGowan","year":"2015","journal-title":"Future Virol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.antiviral.2010.09.005","article-title":"Combining Prevention of HIV-1, Other Sexually Transmitted Infections and Unintended Pregnancies: Development of Dual-protection Technologies","volume":"88","author":"DR Friend","year":"2010","journal-title":"Antiviral Res"},{"issue":"4","key":"ref29","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1517\/17425247.2012.668183","article-title":"Drug Delivery in Multiple Indication (Multipurpose) Prevention Technologies: Systems to Prevent HIV-1 Transmission and Unintended Pregnancies or HSV-2 Transmission","volume":"9","author":"DR Friend","year":"2012","journal-title":"Expert Opin Drug Deliv"},{"issue":"4","key":"ref30","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1517\/17425247.2016.1134485","article-title":"An Update on Multipurpose Prevention Technologies for the Prevention of HIV Transmission and Pregnancy","volume":"13","author":"DR Friend","year":"2016","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"ref31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S1473-3099(16)30550-3","article-title":"The Promise of Multipurpose Pregnancy, STI, and HIV Prevention","volume":"17","author":"M Quaife","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/hec.3297","article-title":"Parameterising User Uptake in Economic Evaluations: The role of discrete choice experiments","volume":"25","author":"F Terris-Prestholt","year":"2016","journal-title":"Health Econ"},{"key":"ref33","article-title":"Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women","author":"JM Baeten","year":"2016","journal-title":"N Engl J Med"},{"key":"ref34","unstructured":"Liu D, Shi B, Wang F, Hung R, Yu C, inventors; Gilead Sciences, Inc., assignee. Tenofovir Alafenamide Hemifumarate. USA patent U.S. Patent 8,754,065 B2. 2014 Jun. 17, 2014."},{"issue":"4","key":"ref35","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1600-0684.2009.00354.x","article-title":"Development and Evaluation of a Vaginal Ring Device for Sustained Delivery of HIV Microbicides to Non-human Primates","volume":"38","author":"N Promadej-Lanier","year":"2009","journal-title":"J Med Primatol"},{"issue":"8","key":"ref36","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1002\/jps.23208","article-title":"An Intravaginal Ring for the Simultaneous Delivery of Multiple Drugs","volume":"101","author":"MM Baum","year":"2012","journal-title":"J Pharm Sci"},{"issue":"2","key":"ref37","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1128\/AAC.05662-11","article-title":"Simultaneous Delivery of Tenofovir and Acyclovir via an Intravaginal Ring","volume":"56","author":"JA Moss","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"ref38","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1128\/AAC.00547-13","article-title":"Pharmacokinetics of a Multipurpose Pod-intravaginal Ring Simultaneously Delivering Five Drugs in the Ovine Model","volume":"57","author":"JA Moss","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"ref39","doi-asserted-by":"crossref","first-page":"5125","DOI":"10.1128\/AAC.02871-14","article-title":"Pharmacokinetics and Preliminary Safety Study of Pod-Intravaginal Rings Delivering Antiretroviral Combinations for HIV Prophylaxis in a Macaque Model","volume":"58","author":"JA Moss","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"ref40","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0010-7824(99)00010-4","article-title":"A Vaginal Fluid Simulant","volume":"59","author":"DH Owen","year":"1999","journal-title":"Contraception"},{"issue":"1","key":"ref41","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1124\/mol.108.045526","article-title":"Activation of 9-[(R)-2-[[(S)-[[(S)-1-(Isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and Other Tenofovir Phosphonoamidate Prodrugs by Human Proteases","volume":"74","author":"G Birkus","year":"2008","journal-title":"Mol Pharmacol"},{"issue":"2","key":"ref42","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1021\/mp3002045","article-title":"Mechanism for Effective Lymphoid Cell and Tissue Loading Following Oral Administration of Nucleotide Prodrug GS-7340","volume":"10","author":"D Babusis","year":"2013","journal-title":"Mol Pharmaceut"},{"issue":"11","key":"ref43","doi-asserted-by":"crossref","first-page":"5952","DOI":"10.1128\/AAC.01198-12","article-title":"Safety and Pharmacokinetics of Intravaginal Rings Delivering Tenofovir in Pig-tailed Macaques","volume":"56","author":"JA Moss","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"ref44","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1089\/aid.2013.0044","article-title":"Single Dose Pharmacokinetics of Oral Tenofovir in Plasma, Peripheral Blood Mononuclear Cells, Colonic Tissue, and Vaginal Tissue","volume":"29","author":"NA Louissaint","year":"2013","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref45","article-title":"Pharmacokinetics of Long-acting Tenofovir Alafenamide (GS-7340) Subdermal Implant for HIV Prophylaxis","author":"M Gunawardana","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"ref46","doi-asserted-by":"crossref","first-page":"e55013","DOI":"10.1371\/journal.pone.0055013","article-title":"MTN-001: Randomized Pharmacokinetic Cross-over Study Comparing Tenofovir Vaginal Gel and Oral Tablets in Vaginal Tissue and Other Compartments","volume":"8","author":"CW Hendrix","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"ref47","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1128\/JVI.05842-11","article-title":"Durable Protection from Vaginal Simian-human Immunodeficiency Virus Infection in Macaques by Tenofovir Gel and its Relationship to Drug Levels in Tissue","volume":"86","author":"C Dobard","year":"2012","journal-title":"J Virol"},{"issue":"1","key":"ref48","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ijpharm.2015.09.028","article-title":"An Intravaginal Ring for the Sustained Delivery of Tenofovir Disoproxil Fumarate","volume":"495","author":"MM Baum","year":"2015","journal-title":"Int J Pharm"},{"issue":"6","key":"ref49","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1128\/AAC.00391-16","article-title":"Combination Pod-intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model","volume":"60","author":"JA Moss","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"issue":"40","key":"ref50","doi-asserted-by":"crossref","first-page":"16145","DOI":"10.1073\/pnas.1311355110","article-title":"Intravaginal Ring Eluting Tenofovir Disoproxil Fumarate Completely Protects Macaques from Multiple Vaginal Simian-HIV Challenges","volume":"110","author":"JM Smith","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"ref51","doi-asserted-by":"crossref","first-page":"10358","DOI":"10.1128\/JVI.01073-09","article-title":"Complete Protection from Repeated Vaginal Simian-human Immunodeficiency Virus Exposures in Macaques by a Topical Gel Containing Tenofovir Alone or with Emtricitabine","volume":"83","author":"UM Parikh","year":"2009","journal-title":"J Virol"},{"issue":"6","key":"ref52","doi-asserted-by":"crossref","first-page":"e0157061","DOI":"10.1371\/journal.pone.0157061","article-title":"Topical Delivery of Tenofovir Disoproxil Fumarate and Emtricitabine from Pod-intravaginal Rings Protect Macaques from Multiple SHIV Exposures","volume":"11","author":"P Srinivasan","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"ref53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088509","article-title":"Engineering a Segmented Dual-reservoir Polyurethane Intravaginal Ring for Simultaneous Prevention of HIV Transmission and Unwanted Pregnancy","volume":"9","author":"JT Clark","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"ref54","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ijpharm.2016.07.051","article-title":"Matrix and Reservoir-type Multipurpose Vaginal Rings for Controlled Release of Dapivirine and Levonorgestrel","volume":"511","author":"P Boyd","year":"2016","journal-title":"Int J Pharm"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jconrel.2015.06.018","article-title":"A Novel Intravaginal Ring to Prevent HIV-1, HSV-2, HPV, and Unintended Pregnancy","volume":"213","author":"SR Ugaonkar","year":"2015","journal-title":"J Control Release"},{"issue":"22","key":"ref56","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa1602046","article-title":"Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women","volume":"375","author":"A Nel","year":"2016","journal-title":"N Engl J Med"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.antiviral.2013.09.019","article-title":"Lessons from Reproductive Health to Inform Multipurpose Prevention Technologies: Don&apos;t Reinvent the Wheel","volume":"100","author":"M Brady","year":"2013","journal-title":"Antiviral Res"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/1471-0528.12851","article-title":"Making the Case for Multipurpose Prevention Technologies: the Socio-epidemiological Rationale","volume":"121","author":"H Boonstra","year":"2014","journal-title":"BJOG"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.addr.2015.02.004","article-title":"Acceptability and Preferences for Vaginal Dosage Forms Intended for Prevention of HIV or HIV and Pregnancy","volume":"92","author":"C Woodsong","year":"2015","journal-title":"Adv Drug Deliv Rev"},{"key":"ref60","unstructured":"Baeten J, Heffron R, Kidoguchi L, Mugo N, Katabira E, Bukusi E, et al., editors. Near Elimination of HIV Transmission in a Demonstration Project of PrEP and ART. 2015 Conference on Retroviruses and Opportunistic Infections (CROI); 2015 Feb. 23\u201326, 2015; Seattle, WA: CROI, Alexandria, VA."},{"key":"ref61","article-title":"Experiences with HPTN 067\/ADAPT Study Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework","author":"KR Amico","year":"2016","journal-title":"AIDS Behav"},{"key":"ref62","unstructured":"Molina J-M, Charreau I, Spire B, Cotte L, Pialoux, Capitant C, et al., editors. On Demand PrEP With Oral TDF-FTC in the Open-Label Phase of the ANRS IPERGAY Trial. 2016 Conference on Retroviruses and Opportunistic Infections (CROI); 2016 Feb. 22\u201325, 2016; Boston, MA: CROI, Alexandria, VA."},{"issue":"6","key":"ref63","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/QAD.0b013e3283509abb","article-title":"Tenofovir and Tenofovir Disoproxil Pharmacokinetics from Intravaginal Rings","volume":"26","author":"JA Moss","year":"2012","journal-title":"Aids"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2016.04.015","article-title":"Tenofovir Alafenamide (TAF) as the Successor of Tenofovir Disoproxil Fumarate (TDF)","volume":"119","author":"E De Clercq","year":"2016","journal-title":"Biochem Pharmacol"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","article-title":"Tenofovir Alafenamide: A Novel Prodrug of Tenofovir for the Treatment of Human Immunodeficiency Virus","volume":"125","author":"AS Ray","year":"2016","journal-title":"Antiviral Res"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.antiviral.2016.05.012","article-title":"High Resistance Barrier to Tenofovir Alafenamide is Driven by Higher Loading of Tenofovir Diphosphate into Target Cells Compared to Tenofovir Disoproxil Fumarate","volume":"132","author":"NA Margot","year":"2016","journal-title":"Antiviral Res"},{"issue":"11","key":"ref67","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1177\/1060028016660812","article-title":"Tenofovir Alafenamide: A Review of Its Use in the Treatment of HIV-1 Infection","volume":"50","author":"AK Gibson","year":"2016","journal-title":"Ann Pharmacother"},{"issue":"2","key":"ref68","first-page":"59","article-title":"Renal and Bone Toxicity with the Use of Tenofovir: Understanding at the End","volume":"18","author":"JL Casado","year":"2016","journal-title":"Aids Rev"},{"issue":"5","key":"ref69","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1128\/AAC.49.5.1898-1906.2005","article-title":"Selective Intracellular Activation of a Novel Prodrug of the Human Immunodeficiency Virus Reverse Transcriptase Inhibitor Tenofovir Leads to Preferential Distribution and Accumulation in Lymphatic Tissue","volume":"49","author":"WA Lee","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"ref70","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3851\/IMP2767","article-title":"Metabolism and Antiretroviral Activity of Tenofovir Alafenamide in CD4<sup>+<\/sup> T-cells and Macrophages from Demographically Diverse Donors","volume":"19","author":"RA Bam","year":"2014","journal-title":"Antivir Ther"},{"issue":"2","key":"ref71","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/00003088-199324020-00002","article-title":"Comparative Pharmacokinetics of Antiviral Nucleoside Analogs","volume":"24","author":"GD Morse","year":"1993","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"ref72","first-page":"754","article-title":"Valaciclovir\u2014A Review of its Antiviral Activity, Pharmacokinetic Properties and Therapeutic Efficacy in Herpesvirus Infections","volume":"52","author":"CM Perry","year":"1996","journal-title":"Drugs"},{"issue":"7","key":"ref73","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1093\/jac\/dks097","article-title":"Intravaginal Ring Delivery of Tenofovir Disoproxil Fumarate for Prevention of HIV and Herpes Simplex Virus Infection","volume":"67","author":"PMM Mesquita","year":"2012","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"ref74","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1128\/AAC.01818-13","article-title":"Vaginally Delivered Tenofovir Disoproxil Fumarate Provides Greater Protection than Tenofovir against Genital Herpes in a Murine Model of Efficacy and Safety","volume":"58","author":"B Nixon","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"ref75","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.chom.2011.08.015","article-title":"Topical Tenofovir, a Microbicide Effective against HIV, Inhibits Herpes Simplex Virus-2 Replication","volume":"10","author":"G Andrei","year":"2011","journal-title":"Cell Host Microbe"},{"issue":"6","key":"ref76","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/clpt.1993.196","article-title":"Pharmacokinetics of the Acyclovir Pro-drug Valaciclovir after Escalating Single-dose and Multiple-dose Administration to Normal Volunteers","volume":"54","author":"S Weller","year":"1993","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"ref77","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1006\/bbrc.1998.9298","article-title":"Direct Evidence for Peptide Transporter (PepT1)-mediated Uptake of a Nonpeptide Prodrug, Valacyclovir","volume":"250","author":"PV Balimane","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"ref78","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1006\/bbrc.1998.8628","article-title":"Valacycloviv: A Substrate for the Intestinal and Renal Peptide Transporters PEPT1 and PEPT2","volume":"246","author":"ME Ganapathy","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"ref79","doi-asserted-by":"crossref","first-page":"e77340","DOI":"10.1371\/journal.pone.0077340","article-title":"Global Expression of Molecular Transporters in the Human Vaginal Tract: Implications for HIV Chemoprophylaxis","volume":"8","author":"M Gunawardana","year":"2013","journal-title":"PLoS One"},{"issue":"8","key":"ref80","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1093\/jac\/dks151","article-title":"Safety and Pharmacokinetics of Acyclovir in Women Following Release From a Silicone Elastomer Vaginal Ring","volume":"67","author":"MJ Keller","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.antiviral.2013.12.004","article-title":"Comparison of the Vaginal Microbial Communities in HSV-2 Seropositive Women Receiving Medicated Intravaginal Rings","volume":"102","author":"LK Ursell","year":"2014","journal-title":"Antiviral Res"},{"issue":"21","key":"ref82","doi-asserted-by":"crossref","first-page":"8333","DOI":"10.1073\/pnas.83.21.8333","article-title":"Phosphorylation of 3&apos;-Azido-3&apos;-deoxythymidine and Selective Interaction of the 5&apos;-Triphosphate with Human Immunodeficiency Virus Reverse Transcriptase","volume":"83","author":"PA Furman","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"ref83","doi-asserted-by":"crossref","first-page":"7204","DOI":"10.1016\/S0021-9258(20)79686-9","article-title":"Phosphorylation of Acyclovir (Acycloguanosine) Monophosphate by GMP Kinase","volume":"255","author":"WH Miller","year":"1980","journal-title":"J Biol Chem"},{"issue":"1A","key":"ref84","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/0002-9343(82)90085-7","article-title":"Pharmacokinetics of Orally-administered Acyclovir in Patients with Herpes Progenitalis","volume":"73","author":"RB Van Dyke","year":"1982","journal-title":"Am J Med"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"429403","DOI":"10.1155\/2011\/429403","article-title":"Multipurpose Prevention Technologies: Biomedical Tools to Prevent HIV-1, HSV-2, and Unintended Pregnancies","volume":"2011","author":"AR Thurman","year":"2011","journal-title":"Infect Dis Obstet Gynecol"},{"issue":"5","key":"ref86","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.contraception.2010.04.012","article-title":"Contraceptive Vaginal Rings: a Review","volume":"82","author":"V Brache","year":"2010","journal-title":"Contraception"},{"issue":"2","key":"ref87","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0010-7824(90)90141-H","article-title":"Microdose Intravaginal Levonorgestrel Contraception: A Multicenter Clinical Trial. 1. Contraceptive Efficacy and Side-Effects","volume":"41","author":"S Koetsawang","year":"1990","journal-title":"Contraception"},{"issue":"4","key":"ref88","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1023\/A:1006748626008","article-title":"Initial UK Experience of the Levonorgestrel-releasing Contraceptive Intravaginal Ring","volume":"15","author":"J Sahota","year":"1999","journal-title":"Adv Contracept"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/13625187.2002.11949331","article-title":"Contraceptive Efficacy and Tolerability with a Novel Combined Contraceptive Vaginal Ring, NuvaRing","volume":"7","author":"F Roumen","year":"2002","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"3","key":"ref90","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.contraception.2004.09.001","article-title":"Efficacy and Safety of a Contraceptive Vaginal Ring (NuvaRing) Compared with a Combined Oral Contraceptive: a 1-Year Randomized Trial","volume":"71","author":"K Oddsson","year":"2005","journal-title":"Contraception"},{"issue":"4","key":"ref91","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1097\/GRF.0b013e318159c07e","article-title":"Contraceptive Vaginal Ring","volume":"50","author":"T Madden","year":"2007","journal-title":"Clin Obstet Gynecol"},{"issue":"17","key":"ref92","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1097\/QAD.0000000000001228","article-title":"An Updated Systematic Review of Epidemiological Evidence on Hormonal Contraceptive Methods and HIV Acquisition in Women","volume":"30","author":"CB Polis","year":"2016","journal-title":"Aids"},{"issue":"17","key":"ref93","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1097\/QAD.0000000000001229","article-title":"Levonorgestrel in Contraceptives and Multipurpose Prevention Technologies: Does this Progestin Increase HIV Risk or Interact with Antiretrovirals?","volume":"30","author":"CB Polis","year":"2016","journal-title":"Aids"},{"issue":"3","key":"ref94","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1055\/s-0036-1571436","article-title":"Emerging Technologies to Prevent Pregnancy and Sexually Transmitted Infections in Women","volume":"34","author":"D Seidman","year":"2016","journal-title":"Semin Reprod Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0185946","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T01:00:38Z","timestamp":1659574838000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0185946"}},"subtitle":[],"editor":[{"given":"Nicolas","family":"Sluis-Cremer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,10,5]]},"references-count":94,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,10,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0185946","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,5]]}}}